Skip to content

Patch test on healthy subjects

Evaluation of dermatological safety by 24hrs patch test under complete occlusion on healthy human subjects

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/05/042600
Enrollment
24
Registered
2022-05-17
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Control Intervention1: Baby Body Lotion, Baby Cream. Baby Shampoo, Baby Body Massage Oil, Baby Hair Oil, Baby Diaper Rash Cream, Baby Talcum Powder: Dosage form: Semi Solid Direction: For external use

Sponsors

ASCLEPIUS WELLNESS PVT LTD
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in age group 18 - 55 years (both the ages inclusive). 2. Healthy male and female subjects. 3. Subjects with Fitzpatrick skin type III to V. 4. Subjects willing to give a written informed consent. 5. Subjects willing to maintain the patch test in position for 24 hours. 6. Willingness to avoid to contact water during course of study. 7. Subject having not participated in a similar investigation in the past one month. 8. Subjects willing to come for regular follow up visits. 9. Subjects ready to follow instructions during the study period. 10. Willingness to avoid intense UV exposure on test site ( sun or artificial UV), during the course of the study.

Exclusion criteria

Exclusion criteria: 1. Subjects having known hypersensitivity to the study product or its constituents. 2. Subjects having clinically significant active dermatitis or skin disease(s) anywhere in the body. 3. Athletes and subjects with history of excessive sweating. 4. Cutaneous disease which may influence the study result. 5. Subjects on oral corticosteroid . 6. Subjects participating in any other cosmetic or therapeutic study. 7. Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness. 8. Pregnant and lactating females.

Design outcomes

Primary

MeasureTime frame
To evaluate the dermatological safety of investigational productTimepoint: Day 0 to Day 7

Secondary

MeasureTime frame
To assess any adverse drug reactionTimepoint: Day 0 to Day 7

Countries

India

Contacts

Public ContactDrAshok Godavarthi

Radiant Research Services Pvt. Ltd

ashok@radiantresearch.in9880999297

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026